Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Osiris Therapeutics, Inc.    OSIR

Delayed Quote. Delayed  - 08/24 03:44:04 pm
5.18 USD   +1.17%
08/18 OSIRIS THERAPEU : Provides Update Regarding NASDAQ Listing Matters
08/17 Osiris Provides Update Regarding NASDAQ Listing Matters
08/05 OSIRIS THERAPEU : Grafix Manuscript Reporting Positive Outcomes of M..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/18/2016 08/19/2016 08/22/2016 08/23/2016 08/24/2016 Date
5.24(c) 5.18(c) 5.2(c) 5.12(c) 5.18 Last
28 625 58 350 19 165 28 392 5 217 Volume
-0.76% -1.15% +0.39% -1.54% +1.17% Change
More quotes
Financials ($)
Sales 2015 94,9 M
EBIT 2015 4,40 M
Net income 2015 2,77 M
Debt 2015 -
Yield 2015 -
Sales 2016 110 M
EBIT 2016 2,75 M
Net income 2016 2,59 M
Debt 2016 -
Yield 2016 -
P/E ratio 2015 64,00
P/E ratio 2016 40,96
Capi. / Sales2015 1,86x
Capi. / Sales2016 1,60x
Capitalization 176 M
More Financials
Company
Osiris Therapeutics, Inc. engages in stem cell research and development of pharmaceutical products.Its regenerative medicine targets dermal burns, pressure ulcers, venous leg, diabetic foot ulcers, and tissue and bone repair.The company was founded by Peter A. Friedli and James S. Burns on December... 
More about the company
Surperformance© ratings of Osiris Therapeutics, Inc.
Trading Rating : - Investor Rating :
More Ratings
Latest news on OSIRIS THERAPEUTICS, INC.
08/18 OSIRIS THERAPEUTICS : Provides Update Regarding NASDAQ Listing Matters
08/17 OSIRIS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continue..
08/17 Osiris Provides Update Regarding NASDAQ Listing Matters
08/05 OSIRIS THERAPEUTICS : Grafix Manuscript Reporting Positive Outcomes of Multicent..
08/04 Grafix® Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex..
06/29 OSIRIS THERAPEUTICS : Change in Directors or Principal Officers, Financial State..
06/14 OSIRIS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
06/10 OSIRIS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
06/06 INVESTIGATION FOR INVESTORS IN SHARE : OSIR) over Potential Wrongdoing by Certai..
06/02 Khang & Khang LLP Announces an Investigation of Claims against Osiris Therape..
More news
Sector news : Bio Therapeutic Drugs
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 4th Update
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 3rd Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
06/10 Osiris chief resigns for medical reasons
06/03 Mesoblast trading halt to stay in place until June 10, bad news expected
06/03 Is It Time To Invest In Stem Cell Biotechs?
05/31 Midday Gainers / Losers
05/31 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Advertisement
Chart OSIRIS THERAPEUTICS, INC.
Duration : Period :
Osiris Therapeutics, Inc. Technical Analysis Chart | OSIR | US68827R1086 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 8,00 $
Spread / Average Target 56%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David A. Dresner President & Chief Executive Officer
Peter A. Friedli Chairman
Frank D. Czworka Chief Operating Officer
Gregory I. Law Chief Financial Officer, Secretary & Treasurer
Alla Danilkovitch Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
OSIRIS THERAPEUTICS, I..-50.67%176
AMGEN, INC.7.44%130 514
GILEAD SCIENCES, INC.-19.49%107 513
CELGENE CORPORATION-4.80%88 371
REGENERON PHARMACEUTIC..-22.52%44 288
VERTEX PHARMACEUTICALS..-19.74%25 023
More Results